BioAtla, Inc. (NASDAQ:BCAB) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET

Company Participants

Bruce Mackle - LifeSci Advisors

Jay Short - Chairman, CEO and Co-Founder

Scott Smith - President

Philippe Martin - Chief of Clinical Development and Operations

Sheri Lydick - Senior Vice President, Commercial Strategy

Richard Waldron - Chief Financial Officer

Conference Call Participants

Anupam Rama - JPMorgan

Tiago Fauth - Credit Suisse

Kelly Shi - Jefferies

Kaveri Pohlman - BTIG

Tony Butler - ROTH Capital

Arthur He - H.C. Wainwright

Operator

Good day, and thank you for standing by. Welcome to the BioAtla First Quarter 2022 Financial Results and Business Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there'll be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions]

I would now like to hand the conference over to Bruce Mackle, LifeSci Advisors. Please go ahead.

Bruce Mackle

Thank you, operator, and good afternoon, everyone. With me today on the phone are Dr. Jay Short, Chairman, CEO and Co-Founder; Scott Smith, President; Philippe Martin, Chief of Clinical Development and Operations, Sheri Lydick, Senior Vice President, Commercial Strategy; and Richard Waldron, Chief Financial Officer.

Earlier today, BioAtla released financial results and a business update for the quarter ended March 31, 2022. A copy of the press release is available on the company's website. Before we begin, I'd like to remind you that statements made during this conference call that are not historical facts are forward-looking statements within the meaning of the federal securities laws, including, but not limited to statements regarding our business plans and prospects, financial and operating performance and expectations, operating costs and expenses, products pipeline, clinical trial and regulatory timing and associated resource requirements, our programs and potential partnerships and the advancement of our CAB technology and product candidates. These forward-looking statements are based upon BioAtla's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties as described in BioAtla's annual report on Form 10-K filed February 28, 2022, and subsequent filings with the Securities and Exchange Commission. Accordingly, you should not place undue reliance on these statements.

All forward-looking statements made during this conference call are based on management's assumptions and estimates as of today, May 4, 2022. BioAtla undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after today, except as required by law.